文献速递肺栓塞与肺血管病

TBX4突变相关肺动脉高压的表型与结局

Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation.
PubMed 文献 · Eur Respir J · 2020-05-14

本研究报道法国肺动脉高压网络中17个家系20例携带TBX4突变的遗传性肺动脉高压患者的临床、功能、影像、组织学及血流动力学特征与结局。患者诊断中位年龄29岁,70%为NYHA III-IV级,中位肺血管阻力13.6 Wood单位,80%有SPS骨骼征象,所有患者DLCO降低。随访中位76个月,1年、3年、5年无事件生存率分别为100%、94%、83%。

要点

  • TBX4相关PAH可发生于出生至成年晚期,常伴骨骼异常但也可不伴。
  • PAH通常严重,伴支气管和肺实质异常,DLCO普遍降低。
  • PAH靶向治疗可带来显著临床改善,中长期生存率较好。

核心结论

  • TBX4突变所致PAH可伴或不伴骨骼异常,年龄跨度从出生至成年晚期,通常严重并伴支气管和肺实质异常。

研究设计与样本

  • 回顾性队列研究,来自法国肺动脉高压网络,纳入17个家系20例携带TBX4突变的遗传性PAH患者。

主要发现

  • 诊断中位年龄29岁(0-76岁),女性与男性比例为3:1。
  • 70%患者为NYHA功能III或IV级,中位肺血管阻力13.6(6.2-41.8)Wood单位。
  • 80%患者存在小髌骨综合征骨骼征象,半数有轻度限制性或阻塞性通气功能障碍,所有患者DLCO降低。
  • HRCT显示支气管异常、支气管周围囊肿、马赛克分布和纵隔淋巴结病。
  • 随访中位76个月,2例死亡、2例肺移植,1年、3年、5年无事件生存率分别为100%、94%、83%。

临床怎么用

  • 对遗传性PAH患者应关注TBX4突变可能,并评估骨骼、肺功能和HRCT支气管肺实质异常。
  • TBX4相关PAH患者可接受PAH靶向治疗,治疗与显著临床改善相关。

局限性

  • 样本量小(20例),来自单国网络,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: TBX4 mutation causes small patella syndrome (SPS) and/or pulmonary arterial hypertension (PAH). The characteristics and outcomes of PAH associated with TBX4 mutations are largely unknown. METHODS: We report the clinical, functional, radiologic, histologic and haemodynamic characteristics and outcomes of heritable PAH patients carrying a TBX4 mutation from the French pulmonary hypertension (PH) network. RESULTS: 20 patients were identified in 17 families. They were characterised by a median age at diagnosis of 29 years (0-76 years) and a female to male ratio of three. Most of the patients (70%) were in New York Heart Association (NYHA) functional class III or IV with a severe haemodynamic impairment (median pulmonary vascular resistance (PVR) of 13.6 (6.2-41.8) Wood units). Skeletal signs of SPS were present in 80% of cases. Half of the patients had mild restrictive or obstructive limitation and diffusing capacity of the lung for carbon monoxide (D LCO) was decreased in all patients. High-resolution computed tomography (HRCT) showed bronchial abnormalities, peri-bronchial cysts, mosaic distribution and mediastinal lymphadenopathies. PAH therapy was associated with significant clinical improvement. At follow-up (median 76 months), two patients had died and two had undergone lung transplantation. One-year, three-year and five-year event-free survival rates were 100%, 94% and 83%, respectively. Histologic examination of explanted lungs revealed alveolar growth abnormalities, major pulmonary vascular remodelling similar to that observed in idiopathic pulmonary arterial hypertension (IPAH) and accumulation of cholesterol crystals within the lung parenchyma. CONCLUSION: PAH due to TBX4 mutations may occur with or without skeletal abnormalities across a broad age range from birth to late adulthood. PAH is usually severe and associated with bronchial and parenchymal abnormalities.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Thoré P, Girerd B, Jaïs X, et al. Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation. Eur Respir J. 2020. PMID: 32079640. doi:10.1183/13993003.02340-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。